Department of Defense scraps $20 million VaxSyn trial

WASHINGTON -- The Department of Defense has decided to scrap a planned $20 million Phase III clinical trial of MicroGeneSys Inc.'s VaxSyn (gp160) AIDS vaccine, and instead use the money to fund a vaccine therapy development program.

The U.S. Army Medical Research and Development Command and NIH will work together "very closely" to develop the vaccine program, an Army spokesman told BioCentury. The program will be announced on March 15, and research proposals will be solicited from industry, universities and others, he said.